Pediatric Heart Transplantation Long-Term Survival in Different Age and Diagnostic Groups: Analysis of a National Database

2017 ◽  
Vol 8 (3) ◽  
pp. 337-345 ◽  
Author(s):  
Tarek Alsaied ◽  
Muhammad S. Khan ◽  
Raheel Rizwan ◽  
Farhan Zafar ◽  
Chesney D. Castleberry ◽  
...  

Background: The purpose of this study was to evaluate differences in long-term survival without the influence of early mortality, and to identify factors associated with one-year conditional ten-year survival after heart transplantation (HTx) across different age and diagnostic groups. Methods: Organ Procurement and Transplant Network data from January 1990 to December 2005 were used. Cohort was divided according to age (infants [<1 year], children [>1-10 years], and adolescents [11-18 years]) and diagnosis (cardiomyopathy and congenital heart disease [CHD]). Factors associated with one-year conditional ten-year survival were identified using multivariable logistic regression and using a case–control design. Results: One-year conditional ten-year survivors included 1,790 patients compared to 1,114 patients who died after the first posttransplant year and within ten years of transplant with a median follow-up of 4.8 years. Predictors of one-year conditional ten-year survival for infants were recipient’s Caucasian race (odds ratio [OR]: 1.9, 95% confidence interval [CI]: 1.3-2.7) and donor–recipient weight ratio (OR: 0.8, 95% CI: 0.6-1); for children: Caucasian race (OR: 1.6, 95% CI: 1.2-2.1), retransplantation (OR: 0.4, 95% CI: 0.2-0.6), and transplantation after the year 2000 (OR: 1.5, 95% CI: 1.1-2.1); for adolescents only Caucasian race (OR: 2.5, 95% CI: 1.9-2.3). In both CHD and cardiomyopathy, adolescents had worse survival compared to infants and children. There was an era effect with improved survival after 2000. Male gender was a predictor of survival in cardiomyopathy group. Conclusion: Predictors of one-year conditional ten-year survival varied among groups. These data and analyses provide important information that may be useful to clinicians, particularly when counseling patients and families regarding expectations of survival after pediatric HTx.

2002 ◽  
Vol 21 (1) ◽  
pp. 87-88
Author(s):  
N. Shiba ◽  
M.C.Y. Chan ◽  
B.W. Kwok ◽  
R.C. Robbins ◽  
H.A. Valantine ◽  
...  

2020 ◽  
Author(s):  
Yiyao Jiang ◽  
Xiangrong Kong

Abstract Objectives This study aimed to identify the incidence rate of Acute kidney injury (AKI) in our center, assess risk factors for one-year mortality, and predict short- and long-term survival after heart transplantation (HTx). Methods This single-center, retrospective study from October 2009 to Jan 2020 analyzed the pre-, intra-, and postoperative characteristics of 87 patients who underwent HTx. AKI was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Risk factors were analyzed by multivariable logistic regression models. The log-rank test was used to compare long-term survival. Results Twenty-six (36.1%) patients developed AKI. The one-year mortality rates in HTx patients with and without AKI were 26.92% and 10.87%, respectively (P > 0.05). Recipients who required renal replacement therapy (RRT) had a one-year mortality rate of 53.85% compared to 10.87% in those without AKI or RRT (P = 0.003). A long cardiopulmonary bypass (CPB) time (OR: 1.622, 95% CI: 1.014 to 2.595, P = 0.044) was positively related to the occurrence of AKI. A high intraoperative urine volume (OR: 0.566, 95% CI: 0.344 to 0.930, P = 0.025) was negatively correlated with AKI. AKI requiring RRT (HR, 6.402; 95% CI, 2.014–20.355, P = 0.002) was a risk factor for death. Overall survival in patients without AKI at 1, 3, and 5 years was higher than that in patients with AKI (P > 0.05). Conclusions AKI is common after HTx and adversely impacts early mortality. A long CPB time and low intraoperative urine volume maybe associated with the occurrence of AKI. AKI requiring RRT could contribute powerful prognostic information to predict short-term survival.


2016 ◽  
Vol 35 (4) ◽  
pp. S286-S287
Author(s):  
E. Bollano ◽  
K. Karason ◽  
C. Hjalmarsson ◽  
S. Bartfay ◽  
B. Daka ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3390
Author(s):  
Mats Enlund

Retrospective studies indicate that cancer survival may be affected by the anaesthetic technique. Propofol seems to be a better choice than volatile anaesthetics, such as sevoflurane. The first two retrospective studies suggested better long-term survival with propofol, but not for breast cancer. Subsequent retrospective studies from Asia indicated the same. When data from seven Swedish hospitals were analysed, including 6305 breast cancer patients, different analyses gave different results, from a non-significant difference in survival to a remarkably large difference in favour of propofol, an illustration of the innate weakness in the retrospective design. The largest randomised clinical trial, registered on clinicaltrial.gov, with survival as an outcome is the Cancer and Anesthesia study. Patients are here randomised to propofol or sevoflurane. The inclusion of patients with breast cancer was completed in autumn 2017. Delayed by the pandemic, one-year survival data for the cohort were presented in November 2020. Due to the extremely good short-term survival for breast cancer, one-year survival is of less interest for this disease. As the inclusions took almost five years, there was also a trend to observe. Unsurprisingly, no difference was found in one-year survival between the two groups, and the trend indicated no difference either.


2017 ◽  
Vol 41 ◽  
pp. 27-31 ◽  
Author(s):  
Buntaro Fujita ◽  
Emir Prashovikj ◽  
Uwe Schulz ◽  
Jochen Börgermann ◽  
Jakub Sunavsky ◽  
...  

1991 ◽  
Vol 66 (8) ◽  
pp. 985-986 ◽  
Author(s):  
M Arico ◽  
E Pedroni ◽  
L Nespoli ◽  
M Vigano ◽  
F Porta ◽  
...  

2017 ◽  
Vol 9 (8) ◽  
pp. 427 ◽  
Author(s):  
Sven Pischke ◽  
Marie C Lege ◽  
Moritz von Wulffen ◽  
Antonio Galante ◽  
Benjamin Otto ◽  
...  

2010 ◽  
Vol 44 (6) ◽  
pp. 373-379 ◽  
Author(s):  
Johan Sjögren ◽  
Fredrik Ljungdahl-Waller ◽  
Erik Senneby ◽  
Björn Ekmehag ◽  
Bansi Koul ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document